MedTrace Logo

Phase IIB Pilot of Atazanavir + Raltegravir

NCT00768989 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 167

Last updated 2012-02-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if the combination of atazanavir and raltegravir taken together is safe and effective in the treatment of human immunodeficiency virus (HIV).

Conditions

Interventions

DRUG

Atazanavir

Capsules, Oral, 300 mg, twice daily, 96 weeks

DRUG

Raltegravir

Tablet, Oral, 400 mg, twice daily, 96 weeks

DRUG

Atazanavir

Capsules, Oral, 300 mg, once daily, 96 weeks

DRUG

Ritonavir

Capsules, Oral, 100 mg, once daily, 96 weeks

DRUG

Tenofovir/Emtricitabine

Tablet, Oral, 300-mg Tenofovir/200-mg Emtricitabine, once daily, 96 weeks

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2010-01-31
Completion
2010-05-31

Countries

  • United States
  • Argentina
  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00768989 on ClinicalTrials.gov